What's in Henry Ford Health System's pipeline?

Henry Ford Health System has 34 drugs in our index: 22 marketed, 0 filed, 1 in Phase 3, 3 in Phase 2, 7 in Phase 1.

Which companies overlap with Henry Ford Health System's portfolio?

Top competitors by shared drug class: Montefiore Medical Center, Sanofi, Pfizer, Hamilton Health Sciences Corporation, Celgene.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/henry-ford-health-system.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Henry Ford Health System — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Henry Ford Health System pipeline: 22 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

22 marketed 0 filed 1 Phase 3 3 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
neostigmine/glycopyrolate	neostigmine/glycopyrolate	marketed	Cholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrolate)	Neurology / Anesthesia
Ropivicaine	Ropivicaine	marketed			Other
Extended-Release Niacin	Extended-Release Niacin	marketed
Intermittent bolus of ropivacaine	Intermittent bolus of ropivacaine	marketed
Smith & Nephew Bioinductive Implant	Smith & Nephew Bioinductive Implant	marketed
Gebauer's Ethyl Chloride	Gebauer's Ethyl Chloride	marketed
Biodesign Otologic graft	Biodesign Otologic graft	marketed
Gentamycin/citrate, Minocycline/EDTA	Gentamycin/citrate, Minocycline/EDTA	marketed	Antimicrobial coating / combination antibiotic		Infectious Disease / Medical Device Infection Prevention
Control (Standard treatment)	Control (Standard treatment)	marketed
Continuous Infusion of ropivacaine	Continuous Infusion of ropivacaine	marketed
Oxycodone Hydrochloride 5 Mg	Oxycodone Hydrochloride 5 Mg	marketed
arformoterol (RR formoterol)	arformoterol (RR formoterol)	marketed	Long-acting beta-2 adrenergic agonist (LABA)	Beta-2 adrenergic receptor (ADRB2)	Respiratory

Therapeutic area mix

Other · 2
Dermatology / Wound Care · 1
Gastroenterology · 1
Hematology · 1
Immunology · 1
Immunology, Rheumatology, Dermatology, Endocrinology · 1
Infectious Disease / Medical Device Infection Prevention · 1
Neurology / Anesthesia · 1
Neurology / Sleep Medicine · 1
Neurology; Dermatology; Aesthetics · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Montefiore Medical Center · 3 shared drug classes
Sanofi · 3 shared drug classes
Pfizer · 3 shared drug classes
Hamilton Health Sciences Corporation · 2 shared drug classes
Celgene · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Aswan University Hospital · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Henry Ford Health System:

Cite this brief

Drug Landscape (2026). Henry Ford Health System — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/henry-ford-health-system. Accessed 2026-05-16.